ImportRefusal LogoImportRefusal

Allergan Pharmaceuticals Ireland

🚨 Critical Risk

FEI: 3002806285 • Westport, Co. MAYO • IRELAND

FEI

FEI Number

3002806285

📍

Location

Westport, Co. MAYO

🇮🇪

Country

IRELAND
🏢

Address

Castlebar Road, , Westport, Co. MAYO, Ireland

Critical Risk

FDA Import Risk Assessment

77.0
LowModerateHighCritical

This firm has an extensive history of FDA import refusals with severe violations.

Statistics

136
Total Refusals
16
Unique Violations
11/17/2025
Latest Refusal
7/3/2003
Earliest Refusal

Score Breakdown

Violation Severity
69.5×40%
Refusal Volume
79.1×30%
Recency
97.0×20%
Frequency
60.7×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

75110×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

11860×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

328045×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

47216×

NO ENGLISH

Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).

7116×

NO LICENSE

The article is subject to refusal of admission under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it appears to be a biological product for which a biologics license is not in effect under the Public Health Service Act, Part F, Subpart 1-Biological Products, Section 351(a), and it is not the subject of an Investigational New Drug application that is in effect. Therefore, it appears to be a new drug under 201(p) of the FD&C Act that it is in violation of section 505(a) of the FD&C Act because it lacks a new drug approval and because it is misbranded under section 502(f)(1)of the FD&C Act because it fails to bear adequate directions for use

34211×

PERSONALRX

The article appears to be a drug which requires a prescription from your doctor.

2374×

NO PMA

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the device appears to be a Class III device and does not appear to have in effect an approved application for premarket approval pursuant to Section 515 of the Act, or an exemption pursuant to Section 520(g)(1).

163×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

273×

DRUG GMPS

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).

842×

RX DEVICE

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a prescription device that appears to not feature a prescription device legend as required by 21 CFR 801.109.

822×

RX LEGEND

The article appears to be a prescription drug without a prescription drug legend as required by Section 503(b)(4).

38471×

FDF4APIGMP

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods and controls used in its manufacture and control do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B). This finished dosage form drug is made using an Active Pharmaceutical Ingredient from a facility that has been found non-compliant with current Good Manufacturing Practice (see Import Alert 66-40; http://www.accessdata.fda.gov/cms_ia/importalert_189.html). You may submit testimony to provide evidence to overcome the appearance of adulteration. The API source for this finished dosage form drug is:

32601×

NO ENGLISH

Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1)

781×

STERILITY

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to have been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health.

24801×

RXPERSONAL

The article appears to be a device which requires a prescription from your doctor.

5081×

NO 510(K)

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.

Refusal History

DateProductViolationsDivision
11/17/2025
58PCZ05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/14/2025
58PCK05ONABOTULINUMTOXINA
3280FRNMFGREG
472NO ENGLISH
Division of Southwest Imports (DSWI)
12/31/2024
58PDP05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/2/2024
66VBY99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
3280FRNMFGREG
Division of Northern Border Imports (DNBI)
11/14/2024
58PAY05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/28/2024
58PCY05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/11/2024
58PAY05ONABOTULINUMTOXINA
472NO ENGLISH
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/27/2024
58PCZ05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/26/2024
58PCZ05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/18/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/18/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/18/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/17/2024
58PCZ05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/17/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/17/2024
58PDR05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Northeast Imports (DNEI)
6/17/2024
58PCZ05ONABOTULINUMTOXINA
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCZ05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/12/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCZ05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCZ05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/10/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/29/2024
58PCZ05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCZ05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/1/2024
65QCY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/30/2024
58PCY05ONABOTULINUMTOXINA
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/6/2024
65QCR02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/12/2024
65QDY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/28/2023
65QDY02BOTOX
118NOT LISTED
237NO PMA
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/3/2023
66VIY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/13/2023
65QIL02BOTOX
118NOT LISTED
342PERSONALRX
Division of West Coast Imports (DWCI)
4/6/2023
65QCL02BOTOX
118NOT LISTED
75UNAPPROVED
Division of West Coast Imports (DWCI)
3/27/2023
65QBP02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/28/2023
65QCK02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/23/2022
65QCZ02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/14/2022
65QCY02BOTOX
84RX DEVICE
Division of Southeast Imports (DSEI)
11/18/2022
65QCP02BOTOX
118NOT LISTED
27DRUG GMPS
Division of West Coast Imports (DWCI)
11/17/2022
65QCZ02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/3/2022
65QCY02BOTOX
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of West Coast Imports (DWCI)
11/1/2022
65QCY02BOTOX
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/24/2022
65QBY02BOTOX
118NOT LISTED
3280FRNMFGREG
Division of West Coast Imports (DWCI)
10/7/2022
65QCY02BOTOX
118NOT LISTED
472NO ENGLISH
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/7/2022
65QDZ02BOTOX
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/30/2022
65KDL10BIMATOPROST (PROSTAGLANDIN)
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/29/2022
65QCZ02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/30/2022
65QCK02BOTOX
118NOT LISTED
237NO PMA
3280FRNMFGREG
84RX DEVICE
Division of Southeast Imports (DSEI)
5/16/2022
79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
118NOT LISTED
237NO PMA
508NO 510(K)
Division of Southeast Imports (DSEI)
5/10/2022
65QCK02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/6/2022
65QCK02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/5/2022
65QCK02BOTOX
3260NO ENGLISH
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/29/2022
65QDL02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/27/2022
65QCK02BOTOX
3280FRNMFGREG
Division of Southeast Imports (DSEI)
4/27/2022
65QCK02BOTOX
118NOT LISTED
342PERSONALRX
472NO ENGLISH
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/18/2022
79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
342PERSONALRX
Division of Southeast Imports (DSEI)
4/4/2022
65QCY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/1/2022
65QCY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/25/2022
65QCL02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/11/2022
79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
118NOT LISTED
237NO PMA
2480RXPERSONAL
3280FRNMFGREG
Division of Southeast Imports (DSEI)
1/7/2022
65QCL02BOTOX
342PERSONALRX
Division of Southeast Imports (DSEI)
9/17/2021
65QDL02BOTOX
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/3/2021
65QAY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/27/2021
65QCK02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/30/2021
65QBY02BOTOX
342PERSONALRX
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/30/2021
65QCY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/19/2021
65RAL99REPLENISHER N.E.C.
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/6/2021
65QCY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/26/2021
60QCY27THIAMYLAL SODIUM (ANESTHETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/19/2021
65QCY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/18/2020
65QBL02BOTOX
71NO LICENSE
Division of Southeast Imports (DSEI)
12/15/2020
65QAK02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/2/2020
65QDY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/2/2020
65QDY02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/29/2020
65QCZ02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/29/2020
65QCZ02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/29/2020
65QCZ02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/3/2020
65QDL02BOTOX
75UNAPPROVED
Division of Southeast Imports (DSEI)

Frequently Asked Questions

What is Allergan Pharmaceuticals Ireland's FDA import refusal history?

Allergan Pharmaceuticals Ireland (FEI: 3002806285) has 136 FDA import refusal record(s) in our database, spanning from 7/3/2003 to 11/17/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Allergan Pharmaceuticals Ireland's FEI number is 3002806285.

What types of violations has Allergan Pharmaceuticals Ireland received?

Allergan Pharmaceuticals Ireland has been cited for 16 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Allergan Pharmaceuticals Ireland come from?

All FDA import refusal data for Allergan Pharmaceuticals Ireland is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.